Salbutamol
Is It Right for You?
A complete guide to Salbutamol — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Salbutamol?
Salbutamol is a short-acting beta-2 adrenergic agonist (SABA) – a class of bronchodilator medication that rapidly relaxes and opens the airways of the lungs. It is the most widely used reliever inhaler in the UK and is the first-line treatment for the immediate relief of asthma symptoms and bronchospasm caused by a range of respiratory conditions. It works within minutes and its effects last for 4 to 6 hours, making it an essential rescue medication for patients with asthma and chronic obstructive pulmonary disease (COPD).
First developed in the late 1960s by Allen & Hanburys (a subsidiary of Glaxo), salbutamol represented a major advance in respiratory medicine as one of the first beta-2 selective bronchodilators – offering the bronchodilating benefits of earlier bronchodilators such as isoprenaline without the significant cardiac side effects caused by non-selective beta stimulation. It is now one of the most prescribed medications in the UK and is included on the World Health Organization's List of Essential Medicines.
Salbutamol is available in several forms: pressurised metered-dose inhaler (pMDI, commonly known as a blue reliever inhaler), dry powder inhaler (DPI), nebuliser solution, oral tablets and syrup, and intravenous formulation for use in hospital settings. It is suitable for adults and children of all ages in appropriate formulations. It is available generically and under brand names including Ventolin, Salamol, and Airomir.
Salbutamol is a prescription-only medication in the UK. A licensed clinician must assess your symptoms and respiratory history before it can be prescribed – which can now be done quickly and conveniently through a telehealth consultation.
What Conditions Is Salbutamol Used For?
Salbutamol is prescribed for conditions involving reversible airway obstruction and bronchospasm:
the primary indication; used as a reliever inhaler to rapidly reverse bronchospasm and relieve symptoms including wheeze, chest tightness, cough, and shortness of breath during an asthma attack or episode of symptoms.
taken 15 to 30 minutes before exercise to prevent exercise-triggered bronchospasm in patients with asthma or exercise-induced bronchoconstriction.
used as a short-acting reliever bronchodilator to reduce breathlessness and wheeze during acute exacerbations and for symptom relief between doses of long-acting bronchodilators.
high-dose nebulised or intravenous salbutamol is used in the acute management of severe and life-threatening asthma attacks in hospital.
nebulised or intravenous salbutamol is used in emergency settings to temporarily lower dangerously elevated potassium levels by driving potassium into cells.
intravenous salbutamol has been used to temporarily suppress premature uterine contractions, though this indication is now less commonly used due to the availability of alternative tocolytics.
Salbutamol relieves asthma symptoms rapidly but does not treat the underlying airway inflammation that causes asthma. Frequent use of salbutamol – more than two or three times per week – is a sign that asthma is not well controlled and that additional preventer treatment (typically an inhaled corticosteroid) is required. If you are using your salbutamol inhaler more frequently than prescribed, contact your clinician for a review of your asthma management plan.
How Does Salbutamol Work?
Salbutamol is a selective beta-2 adrenergic receptor agonist. Beta-2 adrenergic receptors are found predominantly in the smooth muscle of the bronchi (airways) and are part of the body's sympathetic nervous system response. When salbutamol binds to these receptors, it activates a G-protein signalling cascade that increases intracellular levels of cyclic AMP (cAMP) via adenylyl cyclase activation.
Elevated cAMP activates protein kinase A (PKA), which phosphorylates myosin light chain kinase and other downstream targets, ultimately causing relaxation of the smooth muscle cells surrounding the bronchioles. This bronchodilation – widening of the airways – reduces airway resistance, increases airflow, and rapidly reverses the bronchospasm responsible for the wheeze, chest tightness, and breathlessness characteristic of asthma attacks and COPD exacerbations.
Salbutamol's selectivity for beta-2 receptors over beta-1 receptors (which are predominantly found in the heart) minimises unwanted cardiac stimulation at therapeutic inhaled doses. However, at high doses – particularly with nebulised or systemic administration – some beta-1 stimulation occurs, causing the palpitations, tachycardia, and tremor that are recognised side effects of salbutamol.
When inhaled, salbutamol is delivered directly to the airways, achieving high local concentrations with relatively low systemic absorption. This targeted delivery is responsible for its rapid onset of action – typically within 3 to 5 minutes of inhalation – and its favourable therapeutic index when used at recommended inhaled doses. The duration of bronchodilation following a standard inhaled dose is approximately 4 to 6 hours.
Salbutamol also has additional effects on mast cells and basophils in the airways, stabilising them and reducing the release of inflammatory mediators during allergic bronchospasm, though this is a secondary effect compared to its primary smooth muscle relaxation action.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Use a spacer device with a pressurised metered-dose inhaler (pMDI) wherever possible, particularly for children and patients who find it difficult to coordinate breath and actuation. A spacer significantly improves drug delivery to the lungs by eliminating the need for perfect coordination between pressing the inhaler and breathing in, and by reducing the amount of drug deposited in the mouth and throat. Spacers can be prescribed by your clinician.
Correct inhaler technique is critical. Poor inhaler technique is one of the most common reasons for inadequate asthma control. Key steps for pMDI use: shake the inhaler well; breathe out gently; place the mouthpiece between your lips; press the canister as you begin to breathe in slowly and deeply; hold your breath for 10 seconds; breathe out slowly. Your clinician or pharmacist can review your technique.
Wait at least 30 to 60 seconds between puffs if more than one puff is required, to allow the inhaler to recover and deliver a full dose.
Rinse your mouth with water after using your salbutamol inhaler if you notice throat irritation or oral dryness.
Keep your inhaler clean by wiping the mouthpiece with a dry cloth weekly and checking the actuator is not blocked.
Do not use salbutamol more frequently than prescribed. Increasing use of salbutamol reliever is a sign of worsening asthma control and should prompt a review of your preventer therapy, not simply increased reliever use. If you are using your inhaler daily or more than 3 times per week for symptom relief (not exercise prevention), contact your clinician.
In an acute asthma attack, use your salbutamol inhaler with a spacer and take up to 10 puffs one at a time, with 30-second intervals between each puff. If symptoms do not improve after 10 puffs, or if you are very breathless and unable to talk in full sentences, call 999 immediately.
Side Effects of Salbutamol
Salbutamol is generally very well tolerated at recommended inhaled doses. Side effects are most commonly seen at higher doses or with oral and nebulised formulations where systemic absorption is greater.
- Tremor (fine shaking of the hands) – the most commonly reported side effect; caused by beta-2 receptor stimulation in skeletal muscle
- Palpitations or increased heart rate (tachycardia)
- Headache
- Muscle cramps
- Dry mouth or throat irritation
- Nervousness or restlessness
- Mild hypokalaemia (low potassium) – particularly at high doses
- Severe paradoxical bronchospasm – a rare reaction in which salbutamol causes worsening rather than improvement of airway narrowing immediately after inhalation; if this occurs, stop using the inhaler and seek immediate medical attention
- Severe allergic reaction (anaphylaxis) – hives, facial or throat swelling, difficulty breathing, collapse; very rare
- Significant tachycardia or cardiac arrhythmias – particularly at high doses or in patients with pre-existing cardiac conditions
- Significant hypokalaemia – at high doses, salbutamol can cause clinically significant falls in serum potassium, increasing the risk of cardiac arrhythmias; more relevant in acute severe asthma treatment and in patients on diuretics
- Lactic acidosis – rare; associated with high-dose intravenous or nebulised salbutamol; presents with breathlessness, tachycardia, and metabolic abnormalities
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and asthma guidelines highlight that overuse of short-acting beta-2 agonists (more than 3 puffs per week for symptom relief) is associated with poor asthma control and an increased risk of severe asthma attacks and death. If you are using your salbutamol inhaler frequently for symptom relief, this is a signal that your asthma is not well controlled and that your treatment plan needs to be reviewed by a clinician.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting salbutamol.
Non-selective beta-blockers block both beta-1 and beta-2 receptors, directly antagonising the bronchodilating effect of salbutamol and potentially causing severe bronchospasm. Non-selective beta-blockers are contraindicated in patients with asthma. Cardioselective beta-blockers (e.g. bisoprolol, atenolol) have less antagonism at beta-2 receptors but should still be used with caution in asthmatic patients.
MAOIs may potentiate the cardiovascular effects of salbutamol, including tachycardia and hypertension. Caution is required if salbutamol must be used in patients taking MAOIs.
Both salbutamol (at high doses) and potassium-depleting diuretics lower serum potassium. Concurrent use increases the risk of clinically significant hypokalaemia and associated cardiac arrhythmias. Potassium levels should be monitored in patients on diuretics receiving high-dose salbutamol treatment.
These drugs also reduce serum potassium and can enhance the hypokalaemic effect of salbutamol at high doses. In acute severe asthma management, where multiple bronchodilators and systemic corticosteroids may be used simultaneously, potassium levels require close monitoring.
Salbutamol-induced hypokalaemia can increase the risk of digoxin toxicity. Digoxin toxicity manifests as nausea, visual disturbances, and cardiac arrhythmias. Potassium levels should be monitored in patients on digoxin receiving high-dose salbutamol.
Concurrent use may enhance the cardiovascular side effects of salbutamol, including tachycardia and hypertension. Caution is advised and cardiovascular monitoring may be warranted.
Using salbutamol alongside long-acting beta-2 agonists (LABAs) such as salmeterol or formoterol does not produce dangerous interactions at recommended doses, but the combined cardiovascular effects (palpitations, tachycardia) may be additive. Follow prescribing guidance carefully and do not exceed recommended doses of either agent.
Important Warnings
Salbutamol is the first-line treatment for acute asthma, but it is not sufficient for life-threatening asthma attacks. You must call 999 immediately if: your symptoms are not improving after 10 puffs of salbutamol via spacer; you are so breathless you cannot complete a sentence; your lips or fingertips are turning blue; your peak flow is below 33% of your personal best; or you feel your attack is severe or frightening. While waiting for an ambulance, continue taking salbutamol puffs every minute. Do not drive yourself to hospital during a severe asthma attack.
In rare cases, salbutamol can paradoxically cause worsening of bronchospasm immediately after inhalation. If you notice your breathing getting worse immediately after using your inhaler, stop using it and seek emergency medical attention. This is particularly associated with certain formulations and preservatives in nebuliser solutions.
There is well-established evidence linking the overuse of short-acting beta-2 agonists with an increased risk of severe asthma attacks and asthma-related death. Salbutamol should not be used as a substitute for regular preventer therapy. Regular use of three or more salbutamol inhalers per year – equivalent to using reliever more than 3 times per week – is a recognised marker of poorly controlled asthma and should trigger an urgent review of your treatment plan.
High doses of salbutamol – particularly via nebuliser or intravenous infusion – can cause clinically significant falls in serum potassium (hypokalaemia). This is particularly relevant in the management of acute severe asthma where multiple potassium-depleting agents may be used simultaneously. Serum potassium levels should be monitored during high-dose treatment.
Patients with significant cardiovascular disease – including ischaemic heart disease, hypertrophic obstructive cardiomyopathy, or a history of arrhythmias – should use salbutamol with caution, particularly at higher doses. The cardiovascular stimulant effects of salbutamol (tachycardia, palpitations) may be harmful in these patients. Discuss your cardiac history with your clinician before starting salbutamol.
Salbutamol is widely used during pregnancy for the management of asthma and is generally considered safe. Poorly controlled asthma in pregnancy poses significant risks to both mother and foetus, and these risks generally outweigh any theoretical risks from salbutamol use. It is important not to stop or reduce salbutamol during pregnancy without medical advice. Salbutamol passes into breast milk in small amounts and is considered compatible with breastfeeding. Always inform your clinician that you are pregnant or breastfeeding.
Salbutamol can cause hyperglycaemia (raised blood glucose), particularly at high doses or with systemic administration. Patients with diabetes should monitor their blood glucose more closely when receiving high-dose or nebulised salbutamol treatment. Standard inhaled doses at recommended frequency are unlikely to cause clinically significant glucose changes.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Salbutamol FAQs
Yes. A licensed clinician can assess your respiratory symptoms and history via a telehealth consultation and prescribe salbutamol if it is clinically appropriate. Prescriptions are typically sent to your preferred pharmacy the same day, often within minutes of your consultation.
Salbutamol has a rapid onset of action. When inhaled correctly, bronchodilation typically begins within 3 to 5 minutes, with maximum effect achieved within 15 to 20 minutes. Relief of symptoms is usually noticeable within 5 minutes of taking the dose. The duration of effect is approximately 4 to 6 hours.
Salbutamol is classified as a reliever inhaler because it provides rapid, short-term relief of asthma symptoms by relaxing the airway muscles. It does not treat or reduce the underlying inflammation in the airways that causes asthma. This is in contrast to preventer inhalers (typically containing inhaled corticosteroids), which reduce airway inflammation and are taken regularly to prevent symptoms from occurring. Both types of inhaler play different and complementary roles in asthma management.
Ideally, you should not need to use your salbutamol inhaler for symptom relief more than two or three times per week. Using it more frequently than this indicates that your asthma is not well controlled and that your preventer therapy may need to be reviewed or intensified. If you are using your inhaler daily, contact your clinician for an asthma review as soon as possible.
Salbutamol is a short-acting bronchodilator (reliever) that rapidly opens the airways during symptoms. Steroid inhalers (such as beclomethasone, fluticasone, or budesonide) are preventer inhalers that reduce airway inflammation when taken regularly, preventing symptoms from occurring in the first place. Salbutamol works within minutes but does not have a lasting preventative effect. Steroid inhalers take several weeks to produce their full preventative effect. Most patients with asthma above the mildest level benefit from both types of inhaler.
Sit upright and try to stay calm. Take one puff of your salbutamol inhaler via a spacer every 30 to 60 seconds, up to 10 puffs. If your symptoms improve and do not return, you do not need emergency treatment but should contact your GP or asthma nurse for review. If your symptoms do not improve after 10 puffs, call 999 immediately. Continue taking salbutamol every minute while waiting for the ambulance. Do not lie down.
Yes. Taking 2 puffs of salbutamol 15 to 30 minutes before exercise is an effective way to prevent exercise-induced bronchospasm in patients with asthma. If you require pre-exercise salbutamol more than twice a week, this may indicate that your overall asthma control is suboptimal and a review of your preventer treatment may be needed.
In most cases, yes. The blue reliever inhaler is almost universally salbutamol in the UK (100 mcg per actuation in a pressurised metered-dose inhaler). However, if you have been prescribed a different blue or reliever inhaler, always check the label to confirm the active ingredient. Terbutaline (Bricanyl) is another SABA that comes in a white turbohaler but is less commonly prescribed.
Yes. Salbutamol is safe and widely used in children of all ages, including infants, for the management of acute bronchospasm and asthma. For young children, a spacer device with an age-appropriate mask is essential to ensure effective drug delivery. Dosing is guided by age and weight and will be specified by your clinician.
If your salbutamol inhaler is not providing its usual level of relief, or if you find yourself needing it significantly more than usual, this may indicate a deterioration in your asthma that requires medical attention. Contact your GP or asthma nurse for a review of your treatment plan. If your symptoms are severe and not responding to multiple doses of salbutamol, call 999 immediately.